Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hl2351
- Development stage
- Phase 1
- Lead developer
- Handok
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
HL2351 is a novel recombinant fusion protein drug developed as a third-generation biobetter version of long-acting immunofusion proteins. It consists of two human interleukin-1 receptor antagonist (IL-1Ra) components fused to an immunoglobulin Fc fragment. The drug acts primarily as an interleukin 1 receptor antagonist and also inhibits interleukin 6 and suppresses the expression of interleukin 8. Its main therapeutic intent was for inflammatory diseases such as cryopyrin-associated periodic syndromes (CAPS) and rheumatoid arthritis. HL2351 was developed by Genexine in collaboration with Handok[1][3][4][5].
- Other names
- Recombinant human interleukin-1 receptor antagonist hybrid FcrhIL-1Ra-hyFcrhIL1Ra-hyFcrhIL 1Ra-hyFc
02
Targets
IL-1R (Interleukin-1 receptor type 1 (IL-1R1))
Beyond the preview
Go deeper on hl2351.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hl2351.